Objectives: To compare the efficacy of intravenous polymyxin B with other antimicrobials in the treatment of nosocomial Pseudomonas aeruginosa bacteraemia, assessing many potential confounding factors, including optimal dosage regimens of drugs.
Introduction
Pseudomonas aeruginosa is a major cause of nosocomial infections, including bloodstream infections, which are associated with high mortality rates, especially those infections caused by multidrug-resistant (MDR) isolates. 1 Actually, many MDR isolates are only susceptible to polymyxins [polymyxin B and colistin (polymyxin E)], which are old antibiotics that have latterly re-emerged in clinical practice as the last resort therapy for the treatment of MDR Gram-negative bacteria. 2 -4 Their use has been supported by the lack of other treatment options, and by case series suggesting that polymyxins are efficacious and safe. 2 -4 Nonetheless, with a few exceptions, most of these case series are limited by the relatively small number of patients and the lack of a comparative group to provide more robust data on the efficacy of these drugs. 2 -6 Virtually all comparative studies assessed colistin against other drugs and have demonstrated similar efficacy of this drug compared with other antimicrobials, usually b-lactams. 4 Nonetheless, two studies have found that polymyxins were inferior to 'standard' or comparative antimicrobial agents. 5, 6 However, none of these studies has assessed dosage regimens of polymyxins, which have been shown to be strongly associated with clinical outcome. 7, 8 In this study, we compared the efficacy of intravenous polymyxin B with that of other antimicrobials in the treatment of nosocomial P. aeruginosa bacteraemia, assessing potential confounding factors, including optimal dosage regimens of drugs.
Methods

Study design
A retrospective cohort study was performed from January 2004 to December 2009, at a 600 bed teaching hospital (Hospital Sã o Lucas, Porto Alegre, Brazil). All patients who had P. aeruginosa recovered from blood after 48 h of hospital admission, or before 48 h if they had been hospitalized in the last 60 days, were enrolled for the study. They were excluded if they were ,18 years old, if they had received treatment for a period ,48 h, if they have not received appropriate therapy (defined as the administration of an antimicrobial agent with in vitro susceptibility) or if necessary data were not available in medical records. Only the first bacteraemic episode was considered in the analysis. The study was approved by the local ethics committee.
Variables and definitions
The outcome was in-hospital mortality, defined as death for any cause during patients' hospitalization. The onset of infection was defined as the day of the blood culture collection that resulted in the growth of P. aeruginosa. Potential predictors of in-hospital mortality were: age; gender; Charlson co-morbidity score; 9 length of hospital stay before bacteraemia; baseline diseases; mechanical ventilation and intensive care unit (ICU) stay at the onset of infection; baseline creatinine level; development of renal impairment during therapy; presence of other concomitant infections (infections by other organisms at a site other than blood); severe sepsis or septic shock 10 at the onset of infection; severity of bacteraemia classified by Pitt bacteraemia score; 9 primary site of infection (a site of infection defined according to CDC definitions 11 ) where a P. aeruginosa with the same antimicrobial susceptibility profile was recovered; central venous catheter infection (this was also defined if the differential positivity time of culture of blood drawn simultaneously from central venous catheter and peripheral sites was ≥2 h); polymicrobial infection (isolation of another organism from blood at the same moment as P. aeruginosa, excluding coagulase-negative staphylococci in a single blood culture); time to start appropriate therapy; and administration of adequate dosage regimens of the drugs.
Microbiology
All isolates were identified at the microbiology laboratory of our institution. They were routinely identified by the Vitek system (bioMérieux, Marcy l'Étoile, France). Susceptibility was determined by the disc diffusion method and the results were interpreted according to CLSI criteria. 12 
Statistical analysis
All statistical analyses were carried out using SPSS for Windows, version 16.0. Mortality rates were compared using the log-rank test. Variables potentially associated with the outcome were compared between polymyxin B and comparator groups (all other antimicrobial drugs). P values were calculated using x 2 or Fisher's exact test for categorical variables and the Student's t-test or Wilcoxon-Mann-Whitney for continuous variables. Variables for which the P value was ≤0.20 in this analysis were included one by one using a forward stepwise method in a Cox regression model, according their P value. Variables were checked for confounding and collinearity. A P value of ≤0.10 was set as the limit for acceptance and a P value of .0.10 for the removal of new terms in the model. Proportional hazards assumption was graphically checked inspecting the log[2log(S)] plot. All tests were two-tailed and P≤0.05 was considered significant.
Results
Two hundred and fifty-five patients had at least one P. aeruginosa isolate recovered from the blood. Of these, 122 (47.8%) were excluded: 43 (35.2%) did not receive appropriate treatment; 36 (29.5%) died within 48 h of the onset of infection (with or without appropriate treatment); 5 (4.1%) died ,48 h after the onset of appropriate therapy; 20 (16.4%) were ,18 years old; and 18 (14.8%) patients could not have the data retrieved from their medical records. A total of 133 (52.2% of 255) patients were included in the analysis.
Forty-five (33.8%) patients were treated with polymyxin B and 88 (66.2%) were treated with comparators: 24 (27.3%) were treated with cefepime; 16 (18.2%) with imipenem; 15 (17.0%) with ciprofloxacin; 10 (11.4%) with meropenem; 10 (11.4%) with ceftazidime; 7 (8.0%) with aztreonam; and 6 (6.8%) with piperacillin/tazobactam. The overall in-hospital mortality was 41.4% (55/133) and it was significantly higher in patients treated with polymyxin B compared with patients treated with other antimicrobials [30 (66.7%) versus 25 (28.4%), respectively; relative risk (RR) 2.35, 95% confidence interval (CI) 1.59 -3.47; P≤ 0.001]. The mortality rates of patients treated with polymyxin B and comparators were 20.6/1000 patient-days and 9.9/1000 patient-days, respectively (P ¼ 0.002).
The mean average daily dose of polymyxin B was 141+54 mg and this drug was more frequently prescribed every 12 h (33/45 patients, 73.3%), followed by every 24 h (6, 13.3%), every 48 h (3, 6.7%) and by continuous infusion (3, 6.7%). Only 11 (24.4%) of 45 patients treated with polymyxin B received a dose ≥200 mg/day. Most patients in the comparator group received adequate dosage regimens: 17 (70.8%) of 24 patients treated with cefepime; 15 (93.8%) of 16 treated with imipenem; 10 (66.7%) of 15 treated with ciprofloxacin; 10 (100%) of 10 treated with meropenem; 5 (50.0%) of 10 treated with ceftazidime; 6 (85.7%) of 7 treated with aztreonam; and 6 (100%) of 6 treated with piperacillin/tazobactam.
All isolates were susceptible to polymyxin B. The proportions of susceptibility to other drugs in isolates from both polymyxin B and comparators groups were, respectively: 24.4% and 68.2% to amikacin; 13.3% and 62.5% to ciprofloxacin; 15.6% and 65.9% to aztreonam; 11.4% and 69.0% to piperacillin/tazobactam; 8.9% and 84.1% to ceftazidime; 6.7% and 69.3% to cefepime; 9.1% and 71.3% to imipenem; and 8.9% and 70.9% to meropenem.
The comparison of variables potentially associated with in-hospital mortality between polymyxin B and comparators groups is shown in Table 1 . In the final logistic regression model, treatment with polymyxin B, higher Pitt bacteraemia score and the presence of mechanical ventilation at the onset of bacteraemia were significantly associated with in-hospital mortality. Primary bloodstream infection tended to increase the risk of mortality (Table 2) .
Patients treated with polymyxin B presented a nonsignificantly higher rate of ≥50% but ,100% increase of creatinine level from baseline in relation to those treated with comparators [5 (11.1%) of 45 versus 6 (6.8%) of 88; c Total daily dose of ≥6 g of aztreonam, cefepime and ceftazidime (divided into three doses), 1200 mg of ciprofloxacin (divided into two or three doses), 2 g of imipenem (divided into four doses), 3 g of meropenem (divided into three doses) and 13.5 g of piperacillin/tazobactam (divided into three or four doses), or adjusted as indicated in the product drug information package insert, and ≥200 mg/day (2000000 IU/day) polymyxin B, usually divided into two doses. 9 Dose adjustment of polymyxin B for renal impairment was not considered, since total body clearance of this drug is not affected by creatinine clearance. 13 Polymyxin B for P. aeruginosa bacteraemia 177 
JAC
Discussion
Our study suggests that treatment of P. aeruginosa bacteraemia with polymyxin B had lower efficacy, as demonstrated by higher in-hospital mortality, compared with other antimicrobial agents. The risk of in-hospital mortality was almost 2-fold higher for patients treated with polymyxin B after adjustment for potential confounding factors in the multivariate model.
Previous comparative studies have shown similar cure and mortality rates among patients treated with colistin and other antimicrobials, mainly b-lactam agents (particularly carbapenems). 4 Two further studies compared polymyxin B or colistin therapy with ampicillin/sulbactam in the treatment of nosocomial carbapenem-resistant Acinetobacter baumannii infections and colistin with imipenem, meropenem or ampicillin/sulbactam in the treatment of microbiologically documented nosocomial infections, and found that treatment with polymyxins was associated with higher mortality than comparators. 5, 6 However, these studies have not evaluated the dosage regimens as a covariate potentially associated with the outcomes of infections 5, 6 and this might have affected the results, since it has been recently shown that higher doses improve patient outcomes. 7, 8 Nevertheless, despite the fact that dosage regimens were evaluated in our study and that patients treated with polymyxin B had a significantly lower rate of adequate dosages in relation to comparators, this variable did not remain in the final multivariate model. Thus, we can state that polymyxin B therapy was inferior to comparators, regardless of dosage regimens. It should be noted, however, that the low number of patients in the polymyxin B group who received adequate dosage regimens decreased the statistical power to detect an independent association of this variable with mortality in the multivariate model; although, in contrast to what could be expected, patients treated with ≥200 mg/day had a non-statistically significant higher risk of in-hospital mortality compared with those treated with lower doses (data not shown). Patients in the polymyxin B group started appropriate therapy significantly later than patients in the comparator groups, but this variable also did not remain in the final model.
Lastly, we also demonstrated that polymyxin B therapy was associated with a higher incidence of renal toxicity than comparators, but it was not the cause of the lower efficacy of polymyxin B, since this variable was not independently associated with mortality in the final multivariate model. Nonetheless, it should be noted that multivariate analysis was not performed for this outcome.
Our study has the limitations that are characteristic of studies with a retrospective design. However, most of our variables were objective and not affected by a subjective evaluation. Also, the definition of 'adequate dosage regimens of polymyxin B' was based on a recent study by our group that showed that doses ≥200 mg/day were associated with a significantly lower in-hospital mortality, particularly in bacteraemic infections. 8 However, the doses were not calculated per kg of body weight, because it might be an inaccurate variable. Therefore, some patients might have received lower doses, but these doses could be adequate for their body weight. Additionally, susceptibility to polymyxin B was assessed only by disc diffusion that, although standardized by the CLSI, may present serious testing errors.
14 Thus, although isolates might actually have been resistant to polymyxin B, it is possible that this could not be detected by this method. Finally, many patients were excluded from our study, but most exclusions were due to premature death or absence of appropriate therapy; thus, we could not assess these patients.
In summary, our study suggests that intravenous polymyxin B therapy is associated with higher mortality than other antimicrobial drugs in the treatment of P. aeruginosa bacteraemia.
Although not demonstrated in our study, optimization of dosage regimens may decrease this harmful effect. Since polymyxin B treatment may be inferior to treatment with other drugs and new drugs for P. aeruginosa are currently far from the horizon, prevention of the emergence and spread of polymyxin-only-susceptible organisms is of paramount importance. Further prospective studies are still required to confirm a potential inferiority of polymyxins compared with other antimicrobials. Kvitko et al.
